|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
12-LOX and its product HETE are important regulators of retinal NV through modulation of VEGF and PEDF expression and could provide a new therapeutic target to prevent and treat ischemic retinopathy.
|
21228311 |
2011 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis and thus contributes to many vasoproliferative retinopathies including retinopathy of prematurity.
|
25605522 |
2015 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
VEGF as a Trophic Factor for Müller Glia in Hypoxic Retinal Diseases.
|
29721978 |
2018 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis and has been investigated as a candidate gene in a number of conditions, including diabetes and its microvascular complications (e.g., retinopathy and nephropathy).
|
30579324 |
2019 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
VEGF mRNA and protein expression was higher in the OIR and OIR control groups, compared with the normoxia and OIR‑treated groups.
|
30664207 |
2019 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor A (VEGFA) is involved in the pathogenesis of vasoproliferative retinal diseases, such as exudative age-related macular degeneration (AMD).
|
30825671 |
2019 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) plays a pivotal role in the development of neovascularization in both physiological and pathological processes, e.g., developmental and reproductive angiogenesis, proliferative retinopathies, and cancers.
|
9815760 |
1997 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Administration of recombinant VEGF(165)b inhibits ocular angiogenesis in mouse models of retinopathy and age-related macular degeneration, and colorectal carcinoma and metastatic melanoma.
|
19909248 |
2009 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Adrenomedullin Suppresses Vascular Endothelial Growth Factor-Induced Vascular Hyperpermeability and Inflammation in Retinopathy.
|
28322199 |
2017 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Among seven common polymorphisms in the promoter region, 5'-untranslated region (UTR) and 3'UTR of the VEGF gene, genotype distribution of the C(-634)G polymorphism differed significantly (P = 0.011) between patients with (n = 150) and without (n = 118) retinopathy, and the C allele was significantly increased in patients with retinopathy compared with those without retinopathy (P = 0.0037).
|
11978667 |
2002 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Animal models of oxygen-induced retinopathy studies have shown vascular endothelial growth factor (VEGF) to be a key player in the pathogenesis of ROP.
|
27388246 |
2017 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Association between the -634C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes: a meta-analysis.
|
20591524 |
2010 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
At 12 weeks after fenofibrate treatment, serum IL-1β, TNF-α, VEGF, and Lp-PLA2 levels were detected.In PDR and NPDR patients, levels of serum cytokines such as IL-1β (120.56 ± 27.32 pg/mL vs 112.34 ± 19.45 pg/mL vs 82.9 ± 13.8 pg/mL), TNF-α (125.86 ± 25.57 pg/mL vs 109.48 ± 20.15 pg/mL vs 80.7 ± 12.8 pg/mL), VEGF (166.65 ± 37.74 pg/mL vs 148.54 ± 36.27 pg/mL vs 88.97 ± 24.86 pg/mL), and Lp-PLA2 (172.34 ± 45.22 μg/L vs 154.66 ± 40.98 μg/L vs 125.88 ± 38.87 μg/L) were significantly higher than in diabetes patients without retinopathy.
|
28767589 |
2017 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
AXT107 reduced the VEGF-induced vascular leakage that underlies macular edema in ischemic retinopathies and NVAMD.
|
28100839 |
2017 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
CCR7 and VEGF mRNA were expressed at higher levels in the OIR and OIR control groups than in the normoxia and OIR treated groups.
|
28730075 |
2017 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Certain SNPs in intron 2 of the VEGF gene are associated with early progression of retinopathy in Japanese patients with type 1 diabetes, though their contributions were weakened by glycemic exposure.
|
19263526 |
2009 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Changes in Retinal Nerve Fiber Layer Thickness after Multiple Injections of Novel VEGF Decoy Receptor Conbercept for Various Retinal Diseases.
|
27922068 |
2016 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
CNV in PXE-associated retinopathy is believed to be mediated by the action of vascular endothelial growth factor (VEGF).
|
19483196 |
2009 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Exposure to fluctuations of oxygen in the 50/10 oxygen-induced retinopathy model compared to RA was associated with increased PEDF mRNA (p=0.0185), PEDF protein (p<0.0001), or VEGF protein (p<0.0001).
|
21738387 |
2011 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
For the investigation of sevoflurane's effect on angiogenesis, the angiogenesis and VEGF expression in the retina were measured after administering sevoflurane in an oxygen-induced retinopathy mice model.
|
29464332 |
2018 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Functional polymorphisms within vascular endothelial growth factor (VEGF) gene have shown association with various conditions including diabetic neuropathy and retinopathy.
|
21596454 |
2011 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
CTD_human |
Further, SERPINA3K blocked the overexpression of proinflammatory factors, such as VEGF, TNF-alpha, and ICAM-1, in the retina of the OIR model and in cultured retinal cells exposed to hypoxia.
|
19324842 |
2009 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, the concentrations of VEGF are elevated in the aqueous and vitreous humors of patients with proliferative retinopathies such as the diabetic retinopathy.
|
10469350 |
1999 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, the concentrations of VEGF are elevated in the aqueous and vitreous humors of patients with proliferative retinopathies such as the diabetic retinopathy.
|
10494799 |
1999 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Galectin-1 expression imprints a neurovascular phenotype in proliferative retinopathies and delineates responses to anti-VEGF.
|
28455954 |
2017 |